hyoscyamine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
atropine derivatives 1402 101-31-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • hyoscyamine hydrobromide
  • hyoscyamine
  • (-)-Atropine
  • (-)-Hyoscyamine
  • L-Hyoscyamin
  • L-Hyoscyamine
  • l-Atropine
  • hyoscyamine sulfate
The 3(S)-endo isomer of atropine.
  • Molecular weight: 289.38
  • Formula: C17H23NO3
  • CLOGP: 1.30
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 1
  • TPSA: 49.77
  • ALOGS: -2.06
  • ROTB: 5

Drug dosage:

DoseUnitRoute
1.20 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 2000 mg/mL Bocci G, Oprea TI, Benet LZ
EoM (Fraction excreted unchanged in urine) 57 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.00 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 -0.296 High 1
caco2-efflux Caco-2 efflux ratio (BA/AB) 3.381 High 1
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 3.105 10^-6 cm/s High 1
dh-clint Dog hepatocyte intrinsic clearance 9.162 uL/min/10^6 cells High 1
dppb Dog plasma protein binding (% unbound) 89.930 % High 1
fcs-ppb Fetal calf serum protein binding (% unbound) 85.910 % High 1
herg hERG pIC50 4.469 pIC50 High 1
hh-clint Human hepatocyte intrinsic clearance 2.570 uL/min/10^6 cells High 1
hlm-clint Human liver microsomal intrinsic clearance 3.090 uL/min/mg protein High 1
hppb Human plasma protein binding (% unbound) 90.320 % High 1
kinase-safety-class ACVR2A,ACVR2B,AKT2,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,IRAK4,ITK,JAK3,MAP3K21,MAP3K7,MAPK7,MAPKAPK2,MET,NTRK2,PDK2,PDK4,PIM2,PRKDC,SIK2,SIK3,TEK,TGFBR1 35
kinase-selectivity-class AXL,CAMK2D,CDK4,EIF2AK3,PDK4 5
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 1.279 High 1
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 2.547 High 1
mh-clint Mouse hepatocyte intrinsic clearance 188.799 High 1
mppb Mouse plasma protein binding (% unbound) 91.340 High 1
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 6.871 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pld-class Phospholipidosis risk class (1 = positive, 0 = negative) 1 High 1
pppb Pig plasma protein binding (% unbound) 91.360 % High 1
rat-kpuu-brain Rat brain Kpuu 0.049 % High 1
rh-clint Rat hepatocyte intrinsic clearance 87.498 uL/min/10^6 cells High 1
rh-fuinc Rat hepatocyte fraction unbound in incubation 94.180 % High 1
rppb Rat plasma protein binding (% unbound) 85.110 % High 1
solubility-dd Solubility at pH 7.4 in DMSO 903.649 uM High 1

Approvals:

DateAgencyCompanyOrphan
Jan. 1, 1869 YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cholecystitis chronic 160.32 13.83 58 12673 9768 90605948
Biliary dyskinesia 81.05 13.83 25 12706 2574 90613142
Gallbladder disorder 80.34 13.83 44 12687 19759 90595957
Abdominal pain 47.06 13.83 142 12589 395579 90220137
Vision blurred 42.37 13.83 64 12667 110229 90505487
Emotional distress 37.26 13.83 35 12696 36627 90579089
Anticholinergic syndrome 36.69 13.83 14 12717 2729 90612987
Maternal exposure during pregnancy 36.52 13.83 4 12727 360059 90255657
Cholelithiasis 30.08 13.83 37 12694 52469 90563247
Spleen congestion 29.79 13.83 6 12725 104 90615612
Anxiety 28.54 13.83 102 12629 309670 90306046
Diarrhoea 27.38 13.83 225 12506 938965 89676751
Joint swelling 26.84 13.83 19 12712 503281 90112435
Drug intolerance 25.07 13.83 16 12715 447575 90168141
Urinary tract infection 24.30 13.83 96 12635 305536 90310180
Systemic lupus erythematosus 23.06 13.83 11 12720 361885 90253831
Lower respiratory tract infection 22.55 13.83 4 12727 250655 90365061
Dehydration 22.32 13.83 69 12662 194378 90421338
Depression 21.97 13.83 92 12639 300509 90315207
Product dose omission issue 21.89 13.83 90 12641 291597 90324119
Completed suicide 21.04 13.83 56 12675 145002 90470714
Arthropathy 20.62 13.83 13 12718 366229 90249487
Abdominal distension 20.57 13.83 52 12679 130549 90485167
Musculoskeletal stiffness 20.50 13.83 8 12723 296524 90319192
Hepatic enzyme increased 20.04 13.83 13 12718 360723 90254993
Aortic valve calcification 19.35 13.83 6 12725 628 90615088
Biliary colic 19.21 13.83 10 12721 4053 90611663
Small intestinal obstruction 19.17 13.83 19 12712 21215 90594501
Haemorrhoids 18.94 13.83 21 12710 26681 90589035
Nausea 18.82 13.83 238 12493 1110078 89505638
Gallbladder injury 18.68 13.83 7 12724 1299 90614417
Off label use 18.46 13.83 86 12645 1102166 89513550
Urinary incontinence 17.64 13.83 24 12707 37542 90578174
Drug ineffective 17.25 13.83 119 12612 1384179 89231537
Exposure during pregnancy 17.20 13.83 6 12725 238404 90377312
Alopecia 17.07 13.83 27 12704 495044 90120672
Dizziness 17.01 13.83 141 12590 589143 90026573
C-reactive protein increased 16.08 13.83 3 12728 181386 90434330
Muscle spasms 16.04 13.83 74 12657 251809 90363907
Panic attack 15.78 13.83 19 12712 26346 90589370
Balance disorder 15.64 13.83 39 12692 97041 90518675
Hiatus hernia 14.73 13.83 18 12713 25343 90590373
Suicidal ideation 14.44 13.83 32 12699 73823 90541893
Weight decreased 14.40 13.83 97 12634 379813 90235903
Mental disorder 14.21 13.83 20 12711 32298 90583418
Gallbladder cholesterolosis 14.16 13.83 5 12726 783 90614933
Infusion related reaction 14.11 13.83 23 12708 416757 90198959
Pre-existing condition improved 13.88 13.83 11 12720 9158 90606558
Blood testosterone decreased 13.85 13.83 3 12728 75 90615641

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Abdominal pain 26.97 18.76 51 3272 190420 42427592
Faecal calprotectin abnormal 21.39 18.76 5 3318 324 42617688
Hospice care 20.57 18.76 11 3312 8502 42609510
Death 19.28 18.76 80 3243 471105 42146907

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cholecystitis chronic 155.05 14.28 52 11481 9448 110568318
Gallbladder disorder 84.26 14.28 42 11491 20987 110556779
Biliary dyskinesia 72.11 14.28 21 11512 2400 110575366
Abdominal pain 41.90 14.28 133 11400 512856 110064910
Vision blurred 40.28 14.28 58 11475 128964 110448802
Anticholinergic syndrome 34.69 14.28 14 11519 4266 110573500
Emotional distress 34.25 14.28 32 11501 44815 110532951
Cholelithiasis 31.65 14.28 36 11497 63386 110514380
Completed suicide 30.87 14.28 74 11459 242307 110335459
Urinary tract infection 29.77 14.28 88 11445 326194 110251572
Diarrhoea 27.62 14.28 208 11325 1139297 109438469
Muscle spasms 23.46 14.28 73 11460 278084 110299682
Hospice care 22.99 14.28 15 11518 12458 110565308
Dizziness 22.59 14.28 137 11396 698056 109879710
Anxiety 20.79 14.28 81 11452 344997 110232769
Product dose omission issue 20.59 14.28 77 11456 321705 110256061
Spleen congestion 17.88 14.28 5 11528 494 110577272
Cholecystectomy 17.51 14.28 12 11521 10797 110566969
Abdominal pain upper 17.15 14.28 77 11456 349034 110228732
Pain 17.08 14.28 163 11370 954792 109622974
Nausea 17.00 14.28 200 11333 1235490 109342276
Gallbladder injury 16.93 14.28 6 11527 1282 110576484
Drug intolerance 16.60 14.28 11 11522 406501 110171265
Balance disorder 16.37 14.28 37 11496 116523 110461243
Lower respiratory tract infection 15.97 14.28 3 11530 243103 110334663
Abdominal distension 15.73 14.28 47 11486 175056 110402710
Small intestinal obstruction 15.58 14.28 18 11515 32195 110545571
Death 15.43 14.28 125 11408 698744 109879022
Panic attack 15.41 14.28 17 11516 28923 110548843
Treatment failure 15.16 14.28 5 11528 277229 110300537
Maternal exposure during pregnancy 15.03 14.28 4 11529 254879 110322887
Aortic valve calcification 14.98 14.28 5 11528 893 110576873
Systemic lupus erythematosus 14.98 14.28 4 11529 254334 110323432
Depression 14.85 14.28 69 11464 317266 110260500
Dehydration 14.75 14.28 63 11470 279448 110298318

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A03BA03 ALIMENTARY TRACT AND METABOLISM
DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS
BELLADONNA AND DERIVATIVES, PLAIN
Belladonna alkaloids, tertiary amines
ATC A03CB31 ALIMENTARY TRACT AND METABOLISM
DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS
ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS
Belladonna and derivatives in combination with psycholeptics
MeSH PA D000759 Adjuvants, Anesthesia
MeSH PA D000889 Anti-Arrhythmia Agents
MeSH PA D001993 Bronchodilator Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D009184 Mydriatics
MeSH PA D010276 Parasympatholytics
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018678 Cholinergic Agents
MeSH PA D018680 Cholinergic Antagonists
MeSH PA D018727 Muscarinic Antagonists
MeSH PA D018927 Anti-Asthmatic Agents
MeSH PA D019141 Respiratory System Agents
CHEBI has role CHEBI:76924 plant metabolites

Related Drugs by ATC class:

A03BA Belladonna alkaloids, tertiary amines 1 drug
atropine
A03CB Belladonna and derivatives in combination with psycholeptics 3 drugs
atropinemethscopolaminemethylhomatropine

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Peptic ulcer indication 13200003 DOID:750
Dysuria indication 49650001
Sinus bradycardia indication 49710005
Excessive salivation indication 53827007
Gastrointestinal Radiography Adjunct indication
Muscarine Toxicity indication
Cholinesterase Inhibitors Toxicity indication
Urinary Tract Irritation indication
Irritable bowel syndrome off-label use 10743008 DOID:9778
Diarrhea off-label use 62315008
Urinary incontinence off-label use 165232002
Neurogenic bladder off-label use 398064005
Brain damage contraindication 2470005
Ocular hypertension contraindication 4210003 DOID:9282
Gastritis contraindication 4556007 DOID:4029
Hypocalcemia contraindication 5291005
Tachyarrhythmia contraindication 6285003
Suicidal thoughts contraindication 6471006
Urinary tract obstruction contraindication 7163005 DOID:5200
Alcoholism contraindication 7200002
Hyperammonemia contraindication 9360008
Chronic obstructive lung disease contraindication 13645005 DOID:3083
Hepatic encephalopathy contraindication 13920009 DOID:13413
Severe chronic ulcerative colitis contraindication 14311001
Disorder of autonomic nervous system contraindication 15241006
Cirrhosis of liver contraindication 19943007 DOID:5082
Hyperphosphatemia contraindication 20165001 DOID:0050459
Glaucoma contraindication 23986001 DOID:1686
Toxic megacolon contraindication 28536002 DOID:1770
Atony of colon contraindication 29479008
Hyperthyroidism contraindication 34486009 DOID:7998
Depressive disorder contraindication 35489007
Glomerulonephritis contraindication 36171008 DOID:2921
Acute hepatitis contraindication 37871000
Hypertensive disorder contraindication 38341003 DOID:10763
Hypernatremia contraindication 39355002
Hypovolemic shock contraindication 39419009
Gastrointestinal ulcer contraindication 40845000
Complete trisomy 21 syndrome contraindication 41040004 DOID:14250
Body fluid retention contraindication 43498006
Hyperactive behavior contraindication 44548000
Uremia contraindication 44730006 DOID:4676
Conduction disorder of the heart contraindication 44808001
Achalasia of esophagus contraindication 45564002 DOID:9164
Chronic heart failure contraindication 48447003
Disorder of cardiovascular system contraindication 49601007 DOID:1287
Vitamin K deficiency contraindication 52675005 DOID:11249
Nasal polyp contraindication 52756005
Coronary arteriosclerosis contraindication 53741008 DOID:3393
Paralytic ileus contraindication 55525008 DOID:8442
Peptic reflux disease contraindication 57643001
Acute nephropathy contraindication 58574008
Hepatic failure contraindication 59927004
Ulcerative colitis contraindication 64766004 DOID:8577
Blood coagulation disorder contraindication 64779008 DOID:1247
Poisoning by phenobarbital contraindication 64921004
Drug AND/OR toxin-induced diarrhea contraindication 65979008
Substance abuse contraindication 66214007
Hepatic coma contraindication 72836002 DOID:12550
Diabetes mellitus contraindication 73211009 DOID:9351
Sleep apnea contraindication 73430006 DOID:0050847
Factor II deficiency contraindication 73975000
Gastrointestinal hemorrhage contraindication 74474003
Thrombotic thrombocytopenic purpura contraindication 78129009 DOID:10772
Spastic paralysis contraindication 78403003
Disturbance of salivary secretion contraindication 78948009
Chronic idiopathic constipation contraindication 82934008
Hiatal hernia contraindication 84089009 DOID:12642
Kidney disease contraindication 90708001 DOID:557
Thyrotoxicosis contraindication 90739004 DOID:7997
Hemophilia contraindication 90935002
Myasthenia gravis contraindication 91637004 DOID:437
Anemia due to enzyme deficiency contraindication 111577008
Deficiency of glucose-6-phosphate dehydrogenase contraindication 124134002 DOID:2862
Gastrointestinal obstruction contraindication 126765001
Autonomic dysreflexia contraindication 129618003
Bleeding contraindication 131148009
Liver function tests abnormal contraindication 166603001
Myocardial dysfunction contraindication 233928007
Gastroesophageal reflux disease contraindication 235595009 DOID:8534
Disease of liver contraindication 235856003 DOID:409
Bladder outflow obstruction contraindication 236645006
Pyloric obstruction contraindication 244815007
Sleep automatism contraindication 247962006
Benign prostatic hyperplasia contraindication 266569009
Dyspnea contraindication 267036007
Edema contraindication 267038008
Retention of urine contraindication 267064002
Anemia contraindication 271737000 DOID:2355
Drowsy contraindication 271782001
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Neutropenic disorder contraindication 303011007 DOID:1227
Angle-closure glaucoma contraindication 392291006 DOID:13550
Cardiovascular event risk contraindication 395112001
Gastric ulcer contraindication 397825006 DOID:10808
Respiratory insufficiency contraindication 409623005
Breastfeeding (mother) contraindication 413712001
Chronic lung disease contraindication 413839001
Disorder of coronary artery contraindication 414024009
Porphyria contraindication 418470004
Fever greater than 100.4 Fahrenheit contraindication 426000000
Hypertensive urgency contraindication 443482000
Severe dehydration contraindication 450316000
Acute exacerbation of asthma contraindication 708038006




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 13.24 acidic
pKa2 9.26 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Muscarinic acetylcholine receptor M1 GPCR ANTAGONIST Ki 9 WOMBAT-PK KEGG DRUG
Muscarinic acetylcholine receptor M2 GPCR ANTAGONIST Ki 9.30 WOMBAT-PK KEGG DRUG
Muscarinic acetylcholine receptor M3 GPCR ANTAGONIST Ki 9.80 WOMBAT-PK KEGG DRUG
Muscarinic acetylcholine receptor M4 GPCR Ki 9.90 WOMBAT-PK
Muscarinic acetylcholine receptor M5 GPCR Ki 9.20 WOMBAT-PK

External reference:

IDSource
4018400 VUID
N0000189428 NUI
D00147 KEGG_DRUG
306-03-6 SECONDARY_CAS_RN
6835-16-1 SECONDARY_CAS_RN
4018398 VANDF
4018400 VANDF
4018402 VANDF
C0596004 UMLSCUI
CHEBI:17486 CHEBI
CHEMBL1331216 ChEMBL_ID
CHEMBL3989570 ChEMBL_ID
DB00424 DRUGBANK_ID
D064692 MESH_DESCRIPTOR_UI
174174 PUBCHEM_CID
PX44XO846X UNII
1047802 RXNORM
20634 MMSL
4860 MMSL
4861 MMSL
4949 MMSL
6292 MMSL
71952 MMSL
72595 MMSL
d00985 MMSL
001727 NDDF
001728 NDDF
001729 NDDF
372757002 SNOMEDCT_US
387391003 SNOMEDCT_US
48899009 SNOMEDCT_US
56085009 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
URELLE HUMAN PRESCRIPTION DRUG LABEL 5 0037-6321 TABLET 0.12 mg ORAL Unapproved drug other 12 sections
URIBEL HUMAN PRESCRIPTION DRUG LABEL 5 0076-0111 CAPSULE 0.12 mg ORAL unapproved drug other 20 sections
Hyophen HUMAN PRESCRIPTION DRUG LABEL 5 0076-0901 TABLET 0.12 mg ORAL unapproved drug other 19 sections
Phosphasal HUMAN PRESCRIPTION DRUG LABEL 5 0076-0902 TABLET 0.12 mg ORAL unapproved drug other 20 sections
Ustell HUMAN PRESCRIPTION DRUG LABEL 5 0076-0903 CAPSULE 0.12 mg ORAL unapproved drug other 20 sections
URIBEL TABS HUMAN PRESCRIPTION DRUG LABEL 5 0178-0745 TABLET, COATED 0.12 mg ORAL unapproved drug other 13 sections
Belladonna Alkaloids with Phenobartbital HUMAN PRESCRIPTION DRUG LABEL 4 0440-7183 TABLET 0.10 mg ORAL UNAPPROVED DRUG OTHER 14 sections
UROGESIC BLUE HUMAN PRESCRIPTION DRUG LABEL 4 0485-0151 TABLET, COATED 0.12 mg ORAL unapproved drug other 18 sections
UROGESIC BLUE HUMAN PRESCRIPTION DRUG LABEL 4 0485-0151 TABLET, COATED 0.12 mg ORAL unapproved drug other 18 sections
Hyoscyamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 0615-8537 TABLET 0.13 mg ORAL unapproved drug other 18 sections
Hyoscyamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 0615-8554 TABLET 0.13 mg SUBLINGUAL unapproved drug other 18 sections
Uretron D/S HUMAN PRESCRIPTION DRUG LABEL 5 12539-144 TABLET 0.12 mg ORAL unapproved drug other 20 sections
UroAv-81 HUMAN PRESCRIPTION DRUG LABEL 5 15338-502 TABLET 0.12 mg ORAL unapproved drug other 18 sections
UroAv-B HUMAN PRESCRIPTION DRUG LABEL 5 15338-503 CAPSULE 0.12 mg ORAL unapproved drug other 18 sections
Hyoscyamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 16477-738 TABLET, EXTENDED RELEASE 0.38 mg ORAL unapproved drug other 19 sections
Hyoscyamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 16477-738 TABLET, EXTENDED RELEASE 0.38 mg ORAL unapproved drug other 19 sections
Phenohytro HUMAN PRESCRIPTION DRUG LABEL 4 17856-0123 ELIXIR 0.10 mg ORAL UNAPPROVED DRUG OTHER 18 sections
Phenohytro HUMAN PRESCRIPTION DRUG LABEL 4 17856-0125 ELIXIR 0.10 mg ORAL unapproved drug other 19 sections
PHENOBARBITAL WITH BELLADONNA ALKALOIDS HUMAN PRESCRIPTION DRUG LABEL 4 17856-0162 ELIXIR 0.10 mg ORAL unapproved drug other 16 sections
Donnatal HUMAN PRESCRIPTION DRUG LABEL 4 17856-0423 ELIXIR 0.10 mg ORAL unapproved drug other 12 sections
Hyosyne HUMAN PRESCRIPTION DRUG LABEL 1 17856-0511 ELIXIR 0.13 mg ORAL unapproved drug other 11 sections
Hyosyne HUMAN PRESCRIPTION DRUG LABEL 1 17856-0514 ELIXIR 0.13 mg ORAL unapproved drug other 11 sections
Hyoscyamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 21695-442 TABLET 0.13 mg ORAL Unapproved drug other 18 sections
RE-PB HYOS ELIXIR HUMAN PRESCRIPTION DRUG LABEL 4 21695-594 ELIXIR 0.10 mg ORAL Unapproved drug other 11 sections
Belladonna Alkaloids with Phenobartbital HUMAN PRESCRIPTION DRUG LABEL 4 21695-890 TABLET 0.10 mg ORAL Unapproved drug other 15 sections
Hyoscyamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 21695-926 TABLET 0.13 mg ORAL Unapproved drug other 18 sections
QUADRAPAX HUMAN PRESCRIPTION DRUG LABEL 4 21695-970 ELIXIR 0.10 mg ORAL Unapproved drug other 13 sections
URIMAR-T CAPS HUMAN PRESCRIPTION DRUG LABEL 5 28595-224 CAPSULE 0.12 mg ORAL unapproved drug other 19 sections
MB CAPS HUMAN PRESCRIPTION DRUG LABEL 5 28595-299 CAPSULE 0.12 mg ORAL unapproved drug other 18 sections
Hyoscyamine Sulfate Extended-Release HUMAN PRESCRIPTION DRUG LABEL 1 33261-907 TABLET 0.38 mg ORAL UNAPPROVED DRUG OTHER 18 sections